MediWound Ltd. Hits New 52-Week Low at USD 14.14

MediWound Ltd., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 14.14 as of May 27, 2026. This decline marks a significant downturn for the stock, which has experienced a 12.99% decrease over the past year, contrasting sharply with the S&P 500's performance of 27.0% during the same period. The company's market capitalization stands at USD 223 million, and it currently operates at a loss, reflected in its negative price-to-earnings ratio. MediWound's financial metrics indicate challenges, including a return on equity of -41.08% and a debt-to-equity ratio of -1.16. The stock's price-to-book ratio is 4.44, suggesting that it is trading at a premium relative to its book value. MediWound's performance has been characterized by flat results, with operating cash flow hitting a low of USD -12.94 million. Additionally, the inventory turnover ratio has reached a low of 4.59 times, further highlighting the company's current operational difficulties. As the stock continues to navigate these financial hurdles, its recent low underscores the ongoing challenges faced by the company.